Autor segons l'article: Parra, S; Saballs, M; DiNubile, M; Feliu, M; Iftimie, S; Revuelta, L; Pavón, R; Avila, A; Levinson, S; Castro, A
Departament: Medicina i Cirurgia
Autor/s de la URV: Avila Callau, Aitor / Castro Salomó, Antoni / Feliu Masgoret, Mireia / Iftimie Iftimie, Simona Mihaela / Parra Pérez, Sandra
Paraules clau: Mortality Ldl-c, low density cholesterol Ldl Inflammation Hdl-c, high density cholesterol Hdl Covid-19, sars-cov2 disesae Covid-19 Biommarker ldl inflammation impact hdl biommarker
Resum: Background and aims: HDL particles may act to buffer host cells from excessive inflammatory mediators. The aim of this study is to investigate if the lipid profile provides a prognostic biomarker for COVID-19 outcomes. Methods: This was a prospective study of the characteristics of 125 adult COVID-19 patients with a lipid profile performed on the day of admission analyzed with regard to clinical outcomes. Results: Seventy-seven patients (61.2%) were men, with a mean age of 66.3 (15.6) years. 54.1% had bilateral pneumonia. The all-cause mortality rate during hospitalization was 20.8%. We found a direct association between more severe disease assessed by the WHO classification, admission to the ICU and death with more pronounced lymphopenia, higher levels of CRP, ferritin (p < 0.001), D-dímer and lactate dehydrogenase (LDH) all statistically significant. Lower leves of HDL-c and LDL-c were also associated with a worse WHO classification, ICU admission, and death,. HDL-c levels were inversely correlated with inflammatory markers CRP (r = −0.333; p < 0.001), ferritin (r = −0.354; p < 0.001), D-dímer (r = −0.214; p < 0.001), LDH (r = −0.209; p < 0.001. LDL-c levels were significantly associated with CRP (r = −0.320; p < 0.001) and LDH (r = −0.269; p < 0.001). ROC curves showed that HDL [AUC = 0.737(0.586–0.887), p = 0.005] and lymphocytes [AUC = 0.672(0.497–0.847], p < 0.043] had the best prognostic accuracy to predict death. In a multivariate analysis, HDL-c (β = −0.146(0.770–0.971), p = 0.014) and urea (β = 0.029(1.003–1.057), p = 0.027) predicted mortality. Conclusion: Hypolipidemia including HDL levels at admission identifies patients with a higher risk of death and worse clinical manifestations who may require more intensive care.
Àrees temàtiques: Peripheral vascular disease Internal medicine Cardiology and cardiovascular medicine
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: mireia.feliu@urv.cat simonamihaela.iftime@urv.cat aitor.avila@urv.cat aitor.avila@urv.cat aitor.avila@urv.cat sandra.parra@urv.cat antoni.castro@urv.cat
Identificador de l'autor: 0000-0003-0714-8414 0000-0001-9363-6574 0000-0001-5441-6333
Data d'alta del registre: 2024-09-21
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Atherosclerosis Plus. 52 1-8
Referència de l'ítem segons les normes APA: Parra, S; Saballs, M; DiNubile, M; Feliu, M; Iftimie, S; Revuelta, L; Pavón, R; Avila, A; Levinson, S; Castro, A (2023). Low HDL-c levels at admission are associated with greater severity and worse clinical outcomes in patients with COVID-19 disease. Atherosclerosis Plus, 52(), 1-8. DOI: 10.1016/j.athplu.2023.01.002
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2023
Tipus de publicació: Journal Publications
Repositori URV